



## Prominent biotech and healthcare entrepreneur Dr Stephen Parker joins Liverpool ChiroChem as Chairman

*Appointment signals a step-change for specialist chemical supplier to the drug discovery sector*

**Liverpool, UK - 18 July 2017:** [Liverpool ChiroChem Ltd.](#) (LCC), the specialist supplier of chiral small molecules that are used as building blocks, fragments, active pharmaceutical ingredients (APIs) and intermediates in small molecule drug discovery, is pleased to announce the appointment of Dr Stephen Parker as Non-executive Chairman of the company.

The appointment of Dr Parker marks a new growth phase for the Liverpool University spin-out company as it broadens its capabilities across drug discovery, development and manufacturing services, with a growing team of PhD chemists at its R&D centre along with an expanding production laboratory in China.



*Dr Stephen Parker, Chairman of Liverpool ChiroChem Ltd.*

Dr Parker has enjoyed a career spanning over 30 years in the healthcare and pharma sector working both within private and public business. He is currently non-executive Chairman of AIM Listed companies Silence Therapeutics plc and Sareum Holdings Plc and was formerly a partner in the Celtic Pharma funds and Chief Financial Officer at Oxford GlycoSciences. In addition, he has extensive corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apex Partners, where he advised leading chiral science company ChiroScience plc.

**Dr Paul Colbon, CEO of LCC, commented:** "I am delighted to welcome such a high calibre and experienced Chairman to our Board. Dr Parker's appointment comes at a time when the company is raising venture capital and entering more collaborative projects with its

customers, both for which Stephen's significant experience will be of real benefit to our growth."

**Dr Stephen Parker added:** "I am very pleased to be invited to join the Board of Liverpool ChiroChem which in just three years has firmly established itself at the cutting edge of chiral R&D in the UK and has built an impressive customer base. Meanwhile the production operations in China give the company access to this fast emerging drug discovery market. I look forward to working with the company through the next phase of growth and attracting investors looking to gain exposure to this exciting and transformative area of drug development."

**For further information or to request photography please contact:**

Ariane Comstive at Liverpool ChiroChem's PR consultancy, The Communications Portfolio  
[ariane.comstive@communications-portfolio.co.uk](mailto:ariane.comstive@communications-portfolio.co.uk)  
T: + 44 (0)7785 922 354

**Notes to Editors**

About Liverpool ChiroChem

A spin-out from Liverpool University in 2014, Liverpool ChiroChem (LCC) is a chemistry-based contract research organisation (CRO) that produces and supplies chiral small molecules to the pharma and biotech R&D industry. Chiral small molecules form the basis of many pharmaceuticals and drugs being developed today. The company's specialist products can be used as building blocks, fragments, API and intermediates to enable small molecule drug discovery, lead generation and optimisation.

With an R&D team in the UK and production through its laboratories and offices in Jiangsu Province, China, LCC's technologies have been developed through years of research in response to a demand for 'chirally' pure chemicals for use in drugs. The company's patented methods create exceptionally pure chemical forms using a much cheaper and quicker method compared to incumbents.

LCC's highly experienced team includes Prof. Jianliang Xiao, who received the 2008 prize for Process Chemistry Research from the Society of Chemistry and Industry having previously worked alongside [2001 Nobel Prize in chemistry winner Prof. Ryoji Noyori](#), on chiral molecules, and Dr Jianjun Wu who was shortlisted for the Bionow Promising Technologist of the Year Award in 2014.

To date the company has raised £1.1m private equity through VCs and Angel investors, to develop its chemical portfolio and target pharmaceutical R&D companies worldwide. The company counts pharma and biotech companies Merck, Novartis, Domainex, Charles River and Bayer as customers.

**- Ends -**